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Abstract
Background: The cell membrane-derived initiators of coagulation, tissue factor (TF) 
and anionic phospholipid (aPL), are constitutive on the herpes simplex virus type 1 
(HSV1) surface, bypassing physiological regulation. TF and aPL accelerate proteolytic 
activation of factor (F) X to FXa by FVIIa to induce clot formation and cell signaling. 
Thus, infection in vivo is enhanced by virus surface TF. HSV1-encoded glycoprotein 
C (gC) is implicated in this tenase activity by providing viral FX binding sites and in-
creasing FVIIa function in solution.
Objective: To examine the biochemical influences of gC on FVIIa-dependent FX 
activation.
Methods: Immunogold electron microscopy (IEM), kinetic chromogenic assays and mi-
croscale thermophoresis were used to dissect tenase biochemistry. Recombinant TF and 
gC were solubilized (s) by substituting the transmembrane domain with poly-histidine, 
which could be orientated on synthetic unilamellar vesicles containing Ni-chelating lipid 
(Ni-aPL). These constructs were compared to purified HSV1 TF±/gC ± variants.
Results: IEM confirmed that gC, TF, and aPL are simultaneously expressed on a single 
HSV1 particle where the contribution of gC to tenase activity required the avail-
ability of viral TF. Unlike viral tenase activity, the cofactor effects of sTF and sgC on 
FVIIa was additive when bound to Ni-aPL. FVIIa was found to bind to sgC and this 
was enhanced by FX. Orientation of sgC on a lipid membrane was critical for FVIIa-
dependent FX activation.
Conclusions: The assembly of gC with FVIIa/FX parallels that of TF and may involve other 
constituents on the HSV1 envelope with implications in virus infection and pathology.
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1  | INTRODUC TION
Thrombosis and atherosclerosis are major causes of death world-
wide and the incidents are increasing. These diseases have numer-
ous well-established risk factors, which overlap1 and have common 
underlying molecular bases. Viral infection is not typically consid-
ered within the etiology of thrombosis and atherosclerosis,2-4 al-
though numerous viruses have been linked to vascular disease5,6 
and are known to affect the hemostatic system.7-14 As an example, 
herpesviruses persist as lifelong infections and may contribute to 
vascular pathology through frequent reactivation promoting leuko-
cyte and platelet adhesion to the vascular wall, lipid accumulation in 
smooth muscle cells, and thrombin deposition in the periphery.15-18 
Although these examples provide a retrospective clinical correla-
tion, causal evidence was reported using herpes simplex virus 1 
(HSV1) as a targeted cytolytic therapeutic for melanoma cells, 
which resulted in a high propensity for deep vein thrombosis.19 
Case reports have also detailed the presence of thrombi20,21 and/
or bleeding22,23 in patients with HSV1 encephalitis. In one study 
examining predictors of outcome in HSV1 encephalitis, one-half of 
patients experienced acute thrombocytopenia, with ~ 5% reporting 
cerebral hemorrhage.23
To provide a molecular explanation for the clinical evidence, 
our previous studies have demonstrated that members of the her-
pesvirus family incorporate host cell-derived coagulation cofactors 
during assembly of their outer envelope structure.24-26 These are 
the transmembrane protein, tissue factor (TF), and anionic phos-
pholipid (aPL), which function to accelerate the initiation and prop-
agation of coagulation protease activation in response to vascular 
damage. TF is essential for life.27 It accelerates the factor (F) VIIa-
mediated proteolytic activation of FX to FXa by ~100 000-fold.28,29 
FXa subsequently produces the final protease generated during the 
coagulation pathway: thrombin. aPL plays a key role in accelerating 
coagulation protease activation by associating with FVIIa and FX via 
the respective γ-carboxyglutamic acid (Gla)-containing domain to 
enhance the assembly of the protease/substrate/cofactor complex. 
The strict physiological control of TF and aPL on the surface of cells 
is bypassed by their constitutive availability on the virus envelope 
surface. Coagulation enzyme activation on the virus surface and 
consequent induction of cell signaling pathways occur, which have 
pathological implications. An advantage to the virus is enhancement 
of the early events of infection by coagulation enzyme-mediated 
cell signaling, as seen in vitro25 and in vivo.30 When studied in cell 
culture, these effects on infection were facilitated by TF and the 
HSV1-encoded gene product, glycoprotein C (gC), both on the virus 
envelope.
gC is a multifunctional transmembrane glycoprotein that docks 
the virus to host cellular glycosaminoglycans, such as heparan sul-
fate and chondroitin sulfate.31-33 Evasion of host innate immunity is 
also aided by gC, which competes with complement protein C5b for 
binding sites on C3b.34,35 gC expression on HSV1-infected endo-
thelial cells has been linked to monocyte adhesion, possibly contrib-
uting to vascular lesion development.36 This effect was dependent 
on thrombin generation and alluded to a role for gC in coagulation 
protease activation. Further evidence of its coagulation role was 
exemplified by FX binding to cell-surface gC through transgenic 
expression of gC in murine cells.36 Because gC is found on the virus 
envelope, we investigated FX binding to purified HSV1 and showed 
that the presence of viral gC created FX binding sites.37 Although 
a soluble form of gC contributes to FVIIa-dependent FX activation 
without being membrane-tethered, the activity was ~1000-fold 
higher when combined with the virus.38 To explain how viruses may 
contribute to pathology, here we addressed the hypothesis that an 
aPL anchor and interactions with FVIIa and FX are integral to the 
gC-enhanced FX-activating complex, and that the optimal macro-
molecular complex involves viral TF.
2  | MATERIAL S AND METHODS
2.1 | Proteins and reagents
Purified human plasma-derived FVIIa, FX, and FXa, as well as corn 
trypsin inhibitor were purchased from Haematologic Technologies 
(Essex Junction, VT). Recombinant human FVIIa (NovoSeven) was 
gratefully obtained from Novo Nordisk (Mississauga, ON) through 
an unrestricted research grant. Innovin (Dade Behring, Mississauga, 
ON) was the source of liposome-reconstituted purified recombinant 
human TF. Soluble TF (sTF-His)39 was expressed in Escherichia coli 
(strain BL21-DE3) with a His6 tag and 5-amino acid spacer replac-
ing the transmembrane and cytoplasmic domains, and was puri-
fied by nickel affinity chromatography. gC was similarly solubilized 
(gCΔ457t) by substituting the membrane-spanning domain with 
His5 in a baculovirus expression system and was purified using 
rabbit anti-gCΔ457t polyclonal antibody (R118) as previously re-
ported.40,41 Biotin-annexin V was purchased from BioLegend. Goat 
anti-mouse IgG Fc preadsorbed with 6 nm gold particles (ab105285) 
and goat anti-rabbit IgG H&L preadsorbed with 15 nm gold particles 
(ab27236) were purchased from Abcam (Toronto, ON). Goat anti-
biotin preadsorbed with 10 nm gold particles (BBI Solutions) and 
acetylated BSA (Aurion) were commercially obtained (Cedarlane, 
Burlington, ON). Mouse monoclonal anti-TF (TF9-9B4) antibody 
Essentials
• Host tissue factor (TF) and viral glycoprotein C (gC) 
combine to trigger clotting on oral herpes.
• Like TF, gC binds FX and enhances FVIIa-dependent FX 
activation.
• gC also imitates TF by binding FVIIa, which is enhanced 
by FX.
• gC requires orientation on a lipid membrane to function 
as a FVIIa cofactor.
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was produced and purified as before.42 Frozen pooled normal 
human plasma (NP) was obtained from George King Bio-Medical. 
Cyanogen bromide, L-α-phosphatidylserine (brain, porcine, PS), L-α-
phosphatidylcholine (egg, chicken, PC) and the nickel salt of 1,2-di-
oleoyl-sn-glycero-3-[(N-(5-amino-1-carboxypentyl)iminodiacetic 
acid) succinyl] (DOGS-NTA-Ni) were purchased from Sigma Aldrich. 
The FXa-preferred (S-2765) and broad specificity (S-2288) chromo-
genic substrates were from Diapharma (West Chester, Ohio).
2.2 | Viruses
HSV1 NS strain, a clinical isolate that expresses gC (gC+) and ns-1 
strain, a naturally occurring HSV1 mutant that lacks the extracel-
lular domain of gC (gC−) were passaged in African green monkey 
kidney cells (Vero CCL-81; ATCC) to generate initial virus stocks. To 
obtain viruses containing specific combinations of surface gC and/
or TF, NS, or ns-1 were propagated in a human melanoma cell line 
engineered to express TF after treatment with zeocin (A7/TF), as 
described previously.25 Thus, HSV1/TF+/gC+, HSV1/TF+/gC−, HSV1/
TF−/gC+, and HSV1/TF−/gC− viruses were produced in the same cell 
type. Virus concentrations were quantified by negative-staining 
transmission electron microscopy (EM) and the presence or absence 
of viral gC and TF was confirmed by western blot analysis.25 The 
amount of viral TF (~150 molecules/virus particle) was determined 
antigenically by comparison to a purified sTF standard curve using 
densitometry (not shown).
2.3 | Small unilamellar vesicles (SUVs)
Compositions of SUVs (mole %) were: PCPS (20% PS and 80% PC); 
NiPC (15% DOGS-NTA-Ni and 85% PC); and NiPCPS (15% DOGS-
NTA-Ni, 20% PS and 65% PC).43 SUVs were prepared by sonication 
and differential centrifugation, as described previously.44 The con-
centration of lipid was derived after enzymatic hydrolysis using a 
Phospholipids C kit (Wako, Mountain View, CA). Quantified SUVs 
were sized by dynamic light scattering using a Beckman Coulter N4 
PLUS Particle Size Analyzer and were 41 ± 15 nm average diameter.
2.4 | Chromogenic virus-mediated FX activation
All chromogenic experiments were in HBS (20 mmol/L 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 150 mmol/L 
NaCl, pH 7.4) with BSA (0.1%). Virus was first mixed with FX 
(100 nmol/L) and FVIIa (1 nmol/L) in 15 µL followed by addition 
of 5 µL of CaCl2 (calcium, 20 mmol/L) to start the reaction. After 
20 minutes at 37°C with shaking every 5 minutes, 10 µL was 
transferred to a 96-well plate and combined with 90 µL of S-2765 
(200 µmol/L) and EDTA (12 mmol/L). The amount of FXa generated 
was read at 405 nm for 5 minutes at room temperature using a Vmax 
or Spectramax multiwell plate kinetic spectrophotometer (Molecular 
Devices, Sunnyvale, CA). The amount of FX activated was derived 
from a purified FXa standard curve.
2.5 | Immunogold EM
Carbon formvar-coated nickel 400-mesh grids (Electron 
Microscopy Sciences; Cedarlane) were pretreated with 10 µg/mL 
human IgG (tested positive for anti-HSV1 antibodies) to attenu-
ate the deposition of HSV1 as aggregates. Purified HSV1 particles 
(1 × 108 virus particles), sTF-His (10 µg), gCΔ457t (10 µg), PCPS 
(200 µmol/L), or PC only vesicles (200 µmol/L) were adsorbed to 
grids for 5 minutes and then blocked with BSA (5%), fish scale gela-
tin (0.1%), and goat serum (1%) in low-salt HBS (LHBS; 75 mmol/L 
NaCl, 20 mmol/L 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid, pH 7.4) for 40 minutes. Following 2 washes of LHBS, mix-
tures of rabbit anti-gC (R118, 1:50), mouse anti-TF (TF9-9B4, 
5 µg/mL)42 and/or biotin-annexin V (1.25 µg/mL) in LHBS and 
acetylated BSA (0.1%) were layered onto the grid and incubated 
for 1 hour. Samples probed for aPL using annexin V had CaCl2 
(5 mmol/L) included in all buffers and the corresponding control 
included EDTA (10 mmol/L). After five 3-minute washes in LHBS, 
secondary antibody solutions of 6 nm gold-conjugated goat anti-
mouse IgG (1:40), 15 nm gold-conjugated goat anti-rabbit IgG 
(1:160) and 10 nm gold-conjugated goat anti-biotin (1:40) in LHBS 
and acetylated BSA (0.1%) was added and incubated for 45 min-
utes. Following five 3-minute washes in LHBS, the grids were neg-
atively stained with PTA (2%) stain pH 6.5 for 1 minute. The grids 
were wick-dried with filter paper and viewed on a 120 kV Hitachi 
H-7600 transmission electron microscope (Bioimaging Facility, 
University of British Columbia, Vancouver, Canada). HSV1 parti-
cles were defined as particles having gC antigen and a diameter of 
~120-300 nm. The proportion of particles that express TF and/or 
aPL was quantified in 10 squares on the EM grid selected using a 
random number generator (https://numbe rgene rator.org/). Within 
each square, five sections were manually enumerated for a total 
of ~ 500 virus particles for each replicate.
2.6 | gCΔ457t enhancement of FVIIa-mediated 
FX activation
The function of gCΔ457t in FVIIa-mediated FX activation was fol-
lowed by a discontinuous chromogenic assay. Innovin (1:3000) was 
incubated with gCΔ457t (2 µmol/L), FX (0-100 nmol/L), and FVIIa 
(0-10 nmol/L). Calcium (5 mmol/L) was added to initiate the reac-
tion and the mixture was incubated at 3°C for 20 minutes. The 
effect of membrane lipids on FVIIa-mediated FX activation by sTF-
His or gCΔ457t was similarly monitored. PCPS, NiPC, or NiPCPS 
(50 µmol/L) in the presence or absence of gCΔ457t (1.2 nmol/L), 
sTF-His (1 ρmol/L), FX (100 nmol/L), FVIIa (1 nmol/L), or calcium 
(5 mmol/L) were incubated for 20 minutes at 37°C. In all cases, the 
amount of FXa generated was determined by a chromogenic assay.
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2.7 | Equilibrium complex formation by 
microscale thermophoresis
Protein complex formation between gCΔ457t and FVIIa and/or FX 
was assessed using microscale thermophoresis (MST), by quan-
tifying differential mobility in a small temperature gradient be-
cause of complex formation. MST was conducted using a Monolith 
NT.115Pico instrument (NanoTemper Technologies, Munich, 
Germany). To detect thermophoretic shifts of a single species in 
an equilibrium mixture, one protein was covalently labeled with 
an NHS-linked fluorophore using the manufacturer's kit or labeled 
reversibly to study solution-phase interactions through associa-
tion of the poly-His tag with RED-tris-NTA. Fluorophore Alexa 
Fluor 647 succinimidyl ester was purchased from Invitrogen. His-
Tag Labeling Kit RED-tris-NTA and Monolith Protein Labeling 
Kit RED-N-Hydroxysuccinimide (RED-NHS) 2nd Generation was 
from NanoTemper Technologies. Based on the protein concen-
tration determined by colorimetric assays (BCA; Thermo Fisher 
Scientific, Waltham, MA) and the red fluorescent probe extinc-
tion coefficient (239 000 and 195 000 cm/(mol/L) for Alexa Fluor 
647 and NanoTemper Red at 650 nm, respectively), the labeling 
stoichiometries of proteins used here were 1.4, 2.1, and 0.9 for 
Alexa Fluor 647-labeled gCΔ457t, Alexa Fluor 647-labeled sTF-
His, and NanoTemper RED-labeled FVIIa (FVIIa-R), respectively. 
The labeled protein function was comparable to unlabeled in FX 
chromogenic assays in the presence of sTF-His or gCΔ457t.
Microscale thermophoresis measurements were performed at 
25°C with medium MST power and varying LED power to ensure suf-
ficient fluorescence signal. Standard and premium capillaries for MST 
experiments were from NanoTemper. In addition to using BSA as a 
carrier, premium capillaries were specially treated to minimize protein 
adsorption on the capillary wall. Capillaries were cut in half using a 
zirconium blade and nitrogen gas was purged through the capillar-
ies to remove debris. Cut and uncut capillaries gave identical results. 
For solution phase binding, gCΔ457t (200 nmol/L) was mixed with 
the RED-tris-NTA fluorescent probe (3.5 nmol/L) for 30 minutes at 
room temperature before the addition of FX or FVIIa in HBS/BSA 
(0.05%)/Tween-20 (0.05%)/calcium (5 mmol/L). To probe for mem-
brane-bound gCΔ457t interactions, FVIIa-R (2 nmol/L) was titrated 
with gCΔ457t on PCPS, NiPC or NiPCPS (50 µmol/L) vesicles in HBS/
BSA (0.1%)/calcium (5 mmol/L). Benzamidine (2 mmol/L) was also 
included to inhibit protease activity. Equilibrium dissociation con-
stants (Kd values) were derived by fitting data to either a conventional 
binding isotherm equation based on conservation of mass or the Hill 
equation.45,46
2.8 | sTF-His or gCΔ457t binding to FVIIa and SUV
Binding of sTF-His or gCΔ457t to either FVIIa or SUVs were assessed 
using continuous chromogenic assays monitoring FXa generation.43,47 
For SUV binding, varying concentrations of SUVs were mixed in 
HBS containing calcium (5 mmol/L), FVIIa (100 ρmol/L), and either 
gCΔ457t (120 nmol/L) or sTF-His (100 ρmol/L). For FVIIa binding, sTF-
His or gCΔ457t was titrated in HBS with calcium (5 mmol/L), FVIIa 
(10 ρmol/L), and SUVs (100 µmol/L). After 10 minutes of preincubation 
at 25°C, FX (30 nmol/L) and S-2765 (200 µmol/L) was added to start 
the reaction. The amount of FXa generated was immediately moni-
tored spectrophotometrically at 405 nm for 20 minutes.
2.9 | Kinetics of FX activation
To derive Michaelis-Menten kinetic parameters Vmax and Km de-
scribing FVIIa function, initial rates of FX activation were measured 
as reported43 with minor modifications. Reaction mixtures in HBS 
contained calcium (5 mmol/L), FVIIa (500 ρmol/L), and either gCΔ457t 
(10 nmol/L) or sTF-His (10 ρmol/L) with NiPCPS (100 µmol/L). These 
experiments were conducted at concentrations of cofactor that would 
saturate the FVIIa. Varying concentrations of FX were added to initiate 
the reaction at 37°C. Over the course of 10 minutes, 20 µL aliquots 
of the reaction mixture were added to 50 µL stop buffer (Mes-NaOH 
(40 mmol/L), pH 5.8, EDTA (12 mmol/L), NaCl (50 mmol/L), Triton 
X-100 (0.25%), and Antifoam C (0.012%) at 4°C. The stopped reactions 
were rapidly warmed to room temperature, and the amount of FXa 
generated was determined by the addition of S-2765 (200 µmol/L), 
calcium (5 mmol/L), and Tricine-NaOH (0.6 M), pH 8). A standard curve 
was derived using FXa to convert mOD to nmol/L FXa.
2.10 | Plasma clotting
Virus-induced coagulation was monitored using an ST4 coagulation 
analyzer (Diagnostica Stago). In a final reaction volume of 75, 12.5 µL 
of virus and 12.5 µL of HBS was added to 37.5 µL of NP or congeni-
tal FVIII-deficient human plasma. Prewarmed magnetic beads were 
added to the cuvette and incubated for 1 minute at 37°C. Clotting 
was initiated with 12.5 µL of calcium (60 mmol/L). To inhibit contact 
pathway initiation, corn trypsin inhibitor was preincubated with the 
NP for 5 minutes at 37°C. For gCΔ457t-mediated plasma clotting, 
PCPS or NiPCPS (50 µmol/L final concentration) was incubated with 
gCΔ457t (1 µmol/L) and calcium (10 mmol/L) for 5 minutes before 
adding to NP to initiate clotting.
2.11 | Statistical analyses
Data are presented as mean ± standard error of the mean (SEM) 
when three or more replicates were performed. Otherwise, 
mean ± SD was used for controls showing evident effect and a 
n = 2 was reported. The effect of gCΔ457t on virus-mediated FX 
activation was analyzed by unpaired Student t-test. FVIIa amido-
lytic activity data was analyzed by one-way analysis of variance 
(ANOVA). Statistical analysis using t-tests and one-way ANOVA 
were performed using Excel software. Fits of MST data and 
their confidence intervals were derived using quadratic binding 
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isotherm equations written on MathWorks MATLAB® software 
version 2018b (MathWorks).
3  | RESULTS
3.1 | TF, aPL, and gC are simultaneously available on 
the HSV1 surface
To investigate the basis of FX activation on HSV1, the assump-
tion that TF, aPL, and gC are simultaneously available on a single 
virus particle was directly examined by multilabel immunogold EM. 
Figure 1A shows in representative electron micrographs that single 
HSV1 particles carry TF, aPL, and gC. Figure 1B confirmed that the gC 
and TF antibodies, and the aPL probe (i.e., annexin V) were specific 
to the individual components by using irrelevant isotype controls 
on HSV1 or by chelating residual calcium for annexin V. Additional 
controls using recombinant gCΔ457t, sTF-His, PC, and PCPS vesicles 
further confirmed specificity (Figure S1). Virus particles had various 
appearances resulting from variable penetrance of negative staining 
into the envelope, and differential visualization of the virus capsid. 
Quantification of gold labeling revealed that ~ 10% of gC-bearing 
HSV1 particles also had detectable TF and aPL (Figure 1C). Of the 
remaining gC-positive HSV1 particles, ~20% also had detectable TF, 
whereas another ~ 20% had aPL. These images verify that the virus 
surface contains combinations of procoagulant cofactors.
F I G U R E  1   TF, aPL, and gC are simultaneously available on the HSV1 surface. (A) Representative immunogold electron micrographs 
concurrently identifying the HSV1 marker, gC (15 nm gold bead), aPL (10 nm bead), and TF (6 nm gold bead). (B) Individual controls for 
specificity using gold-labeled irrelevant isotype antibody controls for gC and TF or biotinylated-annexin V in the absence of calcium. (Scale 
bars = 100 nm. n = 3). (C) The proportion of gC-positive HSV1 particles that express TF, aPL, or TF and aPL was determined by immunogold 










































     |  1375LIN et aL.
3.2 | Viral gC enhances HSV1-initiated FX activation 
when viral TF is present
To dissect the FX-activating mechanism on the HSV1 surface, the 
effect of purified HSV1/TF+/gC+, HSV1/TF+/gC-, HSV1/TF-/gC+, 
or HSV1/TF-/gC- on FVIIa function was compared using a chro-
mogenic assay. Compared with the fully competent HSV1/TF+/gC+ 
(Figure 2A), both TF-deficient viruses had < 2% FVIIa-mediated FX 
activation (Figure 2B). The presence of gC on the TF-deficient virus 
had no measurable enhancement on FX activation (Figure 2B). The 
small concentration-dependent increase in FX activation resulting 
from HSV1/TF-/gC- suggested that additional constituents such as 
envelope aPL contribute to FX activation. Interestingly, the pres-
ence of viral gC and viral TF enhanced the activation of FX ~ 2.5-fold 
relative to HSV1/TF+/gC- (Figure 2A). When gCΔ457t was added to 
1 × 105 vp/µL of purified HSV1 variants, FX activation was further 
increased on TF-bearing virus (Figure 2C). HSV1/TF+/gC+ exhibited 
a greater enhancement by gCΔ457t compared with HSV1/TF+/gC-. 
Addition of gCΔ457t to TF-deficient virus had no measurable effect 
on FX activation (Figure 2D). Thus, viral TF is required for a contribu-
tion of gC or gCΔ457t to FVIIa activity mediated by purified HSV1. 
FX activation in the absence of FX, FVIIa or calcium was negligible 
(Figure 2E) demonstrating that purified virus has insignificant intrin-
sic hydrolytic activity toward S-2765.
3.3 | gCΔ457t enhances FVIIa-mediated FX 
activation on vesicles
To exclude other virus- or host-encoded factors associated with the 
envelope of HSV1, gCΔ457t was added to lipidated full-length TF 
and aPL (Innovin). gCΔ457t enhanced FX activation by FVIIa with 
saturable dependence on FVIIa (Figure 3A) or FX (Figure 3B). Under 
these conditions, the addition of gCΔ457t increased maximal activa-
tion by ~ two-fold.
sTF-His is known to enhance FX activation by FVIIa optimally 
when DOGS-NTA-Ni is incorporated into an aPL-containing mem-
brane,43 where DOGS-NTA-Ni facilitates membrane binding of sTF-
His and the aPL enables Gla-domain-dependent membrane-binding 
of FVIIa and FX. Thus, the respective contributions toward increas-
ing the activity of FVIIa by gCΔ457t were evaluated by compar-
ing vesicles of various lipid composition, PCPS, NiPC, and NiPCPS. 
Significant FX activation by FVIIa was not observed in the absence 
of sTF-His or gCΔ457t (Figure 3C, bars 1-3). Expression of gCΔ457t 
(Figure 3C, bars 4-6) or sTF-His (not shown) activity was depen-
dent on FVIIa, FX, and calcium ions. As a positive control for the 
anticipated activity of the three vesicle compositions, FX activa-
tion was shown to be enhanced by sTF-His in the following order 
NiPCPS > NiPC» PCPS (Figure 3C, bars 7-9). Interestingly, gCΔ457t 
also enhanced FVIIa activity and followed the same lipid composi-
tion dependence as sTF-His, where combined binding of the His-
tagged cofactor and Gla-containing proteins facilitated by NiPCPS 
was optimal (Figure 3C, bars 10-12). To explore the apparent syn-
ergistic effect of gC and TF on the virus (Figure 2), sTF-His was 
combined with gCΔ457t (Figure 3C, bars 13-15). Unlike the HSV1 
variant experiments, the effect of gCΔ457t on sTF-His was addi-
tive in these purified protein experiments when the cofactor/en-
zyme/substrate complex was assembled on NiPCPS (ie, bar 9 + bar 
12 = bar 15).
Further demonstrating a gCΔ457t cofactor effect on FVIIa, 
incubation with NP shortened clotting times in the presence of 
NiPCPS (Figure 3D, bar 1). With the substitution of NiPCPS for PCPS 
(Figure 3D, bar 2) the majority of samples did not form a clot during 
the experimental time (15 minutes). Similarly, gCΔ457t without lipids 
or the absence of gCΔ457t with either PCPS or NiPCPS yielded spo-
radic clotting with the majority not forming a clot (Figure 3D, bars 3-5, 
respectively). Of note, the NP contained antibodies that recognize 
F I G U R E  2   gC enhances HSV1-initiated FX activation when viral 
TF is present. (A, B) Purified FX (100 nmol/L) and FVIIa (10 nmol/L) 
were combined with HSV1/TF+/gC+ (●), HSV1/TF+/gC− (○), HSV1/
TF−/gC+ (◼) and HSV1/TF−/gC− (◻) viruses in the presence of 
calcium (5 mmol/L) and FXa generation was followed using the 
chromogenic substrate S-2765. (C, D) FX activation by HSV1 was 
followed as in A and B and the effect of adding purified gCΔ457t to 
the panel of HSV1 (1 × 105 vp/µL) was monitored. (E) FX activation 
with 1 × 105 vp/µL HSV1/TF+/gC+, HSV1/TF+/gC−, HSV1/TF−/
gC+, and HSV1/TF−/gC− with (first bar) or without FX, FVIIa, 
or calcium (following bars in order). (A-D: n = 4 ± SEM, *P < .05, 
**P < .01; E: virus and no FVIIa: n = 4 ± SEM, no FX or no Ca2+: n = 2 
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HSV1 and gCΔ457t (Figure S2), accredited to the prevalence of 
HSV1 within the general adult population, which may have affected 
gCΔ457t clotting activity.
3.4 | FX enhances the interaction between 
gCΔ457t and FVIIa
The His-tag of gCΔ457t was non-covalently conjugated to fluores-
cent RED-tris-NTA and monitored by MST to follow interactions 
with FX (Figure 4A) or FVIIa (Figure 4B) in the absence of vesicles. 
Although an interaction between gCΔ457t and FVIIa or FX was 
demonstrable, both were relatively weak as the binding isotherms 
did not approach saturation at the highest available concentration 
of either ligand. These binding isotherms could not be fit to a bind-
ing model with statistical confidence. Although the solution-phase 
F I G U R E  3  gCΔ457t enhances FVIIa-mediated FX activation. 
(A) FX activation by relipidated full-length TF (1:3000; Innovin) 
was followed chromogenically in the presence (●) or absence (○) 
of gCΔ457t (2 µmol/L) at constant FX (100 nmol/L, A) or FVIIa 
(10 nmol/L, B) and titrating either FVIIa (A) or FX (B). (C) FX activation 
was monitored by variably assembling tenase constituents on PCPS, 
NiPC, or NiPCPS (50 µmol/L) in the presence or absence of gCΔ457t 
(1.2 nmol/L), sTF-His (1 ρmol/L), FX (100 nmol/L), FVIIa (1 nmol/L), or 
calcium (5 mmol/L) with 20 minutes incubation at 37°C. (D) Normal 
pooled human plasma clotting time was monitored after initiation 
by gCΔ457t (1 µmol/L), 50 µmol/L PCPS or NiPCPS, and calcium 
(10 mmol/L). (A-C: n = 3 ± SEM; D: n = 3, box plot of pooled replicates; 
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F I G U R E  4   FX enhances the interaction between gCΔ457t and 
FVIIa. MST traces demonstrating weak associations of (A) FX and 
(B) FVIIa with gCΔ457t noncovalently labeled with RED-tris-NTA 
in the absence of membrane associations. (C) MST was also used 
to follow gCΔ457t binding to fluorescent FVIIa-R (2 nmol/L) in 
the presence of PCPS (●), NiPC (◻), or NiPCPS (▲) (50 µmol/L) and 
benzamidine to inhibit FVIIa. (D) Similar to (C) but with the inclusion 
of FX (30 nmol/L). (E) Effects on FVIIa catalytic activity was 
assessed by following FVIIa (2 nmol/L) cleavage of chromogenic 
substrate S-2288 in the presence of gCΔ457t (1 µmol/L) or sTF-His 
(1 nmol/L) with calcium (5 mmol/L) and PCPS (white bars), NiPC 
(gray bars), or NiPCPS (black bars) (50 µmol/L). (All graphs: n ≥ 3 ± 
SEM). P values are provided as determined by 1-way ANOVA.  
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enhancement of FVIIa activity was independent of labelling the 
gCΔ457t with RED-tris-NTA via the poly-His tag, it could not be 
used to follow membrane-associated complex assembly because it 
quantitatively blocked NiPCPS-binding (not shown).
To follow the effects of membrane orientation and the presence of 
FX on incorporation of FVIIa into the gCΔ457t/FX complex, the FVIIa 
was fluorophore-labeled via amine coupling (FVIIa-R). As measured by 
MST, the dissociation constant (Kd) of ~1 nmol/L (Table 1) was ~ 100-
fold higher than the reported Kd value for FVIIa binding to sTF-His/
NiPCPS that was derived using a FXa product-linked chromogenic assay 
(~10 ρmol/L).43 To reconcile this discrepancy, FX was included in the MST 
studies to mimic the conditions of the reported chromogenic method. In 
the presence of excess benzamidine to prevent proteolysis, FX enhanced 
sTF-His/NiPCPS-binding to FVIIa-R by ~ 30-fold (Kd = ~30 ρmol/L; 
Figure S3), which was consistent with the previous report.
gCΔ457t assembled onto NiPC or NiPCPS exhibited greater af-
finity for FVIIa-R compared with vesicles without DOGS-NTA-Ni 
(Figure 4C). This interaction was only moderately affected by the 
presence of PS, implying that a FVIIa-R-membrane interaction may 
not be important; the Kd values were 1.6 and 0.8 µmol/L for NiPC or 
NiPCPS, respectively (Table 1). Binding of gCΔ457t to FVIIa-R in the 
presence of PCPS was detectable in the absence of DOGS-NTA-Ni 
but was not quantifiable (Kd > 13 µmol/L) and consistent with the 
concentration range used for gCΔ457t binding to FVIIa in the ab-
sence of vesicles (Figure 4B). In the presence of NiPC or NiPCPS, 
the addition of FX (Figure 4D) increased the gCΔ457t-FVIIa-R affin-
ity ~ 2-fold (Kd values of 1.0 and 0.4 µmol/L, respectively) indicating 
that Gla-dependent associations are not required for this enhance-
ment. gCΔ457t emulated the FVIIa-sTF-His binding enhancement by 
FX, but this was modest in comparison to the ~ 30-fold observed for 
the latter (Table 1). Omission of DOGS-NTA-Ni reduced the affin-
ity for FVIIa-R binding to gCΔ457t in the presence of FX and PCPS 
(Kd = 2.7 µmol/L).
Direct functional effects conferred to the FVIIa catalytic site 
by gCΔ457t was monitored by following chromogenic substrate 
cleavage (S-2288). Figure 4E shows that at 1 µmol/L gCΔ457t, 
FVIIa-mediated cleavage of S-2288 was enhanced. This result was 
independent of DOGS-NTA-Ni or PS availability. sTF-His also en-
hanced S-2288 cleavage by FVIIa but, unlike gCΔ457t, was further 
enhanced in the presence of DOGS-NTA-Ni. gCΔ457t was less effi-
cient than sTF-His at directly affecting FVIIa amidolytic activity by 
~3700-fold on a molar basis (Figure 4E).
3.5 | gCΔ457t- and sTF-His-binding to Ni-chelating 
vesicles and FVIIa are similar by kinetics
To understand the mechanism of gCΔ457t cofactor function in our 
model system further, the His-tag equilibrium with NiPCPS and NiPC 
was determined by measuring the kinetically linked activation of FX. 
The availability of PS (Figure 5A) in NiPCPS increased the maximal 
TA B L E  1   FVIIa binding to cofactors determined by MST in the 
presence or absence of FX
Ligand Lipid
No FX





sTF-His NiPCPS 8.2 × 10−4 
(8.6 × 10−5-
1.5 × 10−3)
3.0 × 10−5 
(8.0 × 10−6-
5.2 × 10−5)
gCΔ457t NiPC 2.0 (1.3-2.8) 0.9 (0.7-1.0)
gCΔ457t NiPCPS 1.3 (0.8-1.7) 0.6 (0.2-0.9)
gCΔ457t PCPS >13.0 2.2 (0.9-3.5)
gCΔ457t None >12.0 2.9 (1.5-4.2)
F I G U R E  5   gCΔ457t- and sTF-His-binding to Ni-chelating 
vesicles and FVIIa are similar by kinetics. FX (30 nmol/L) activation 
by FVIIa (100 ρmol/L) was followed in the presence of gCΔ457t 
(120 nmol/L, ●) or sTF-His (100 ρmol/L, ◼), calcium (5 mmol/L) 
and titrated with (A) NiPCPS or (B) NiPC. Binding of cofactors to 
FVIIa was followed in a similar manner except FVIIa (10 ρmol/L), 
FX (30 nmol/L), calcium (5 mmol/L), and NiPCPS (50 µmol/L, C) or 
NiPC (50 µmol/L, D), were titrated with gCΔ457t (●) or (◼) sTF-His. 
E. The kinetic parameters of FXa generation by FVIIa (Table 3) was 
determined by deriving the initial FX activation rate by a limiting 
concentration of FVIIa (10 ρmol/L) in the presence of gCΔ457t 
(120 nmol/L, ●) or sTF-His (100 ρmol/L, ◼) with FX, calcium 
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FX activation rate by > 15-fold for both sTF-His and gCΔ457t com-
pared to NiPC. sTF-His and gCΔ457t had similar apparent binding 
affinities (Figure 5B) for either NiPCPS or NiPC (Kd,app = 48 and 
34 µmol/L, respectively), as summarized in Table 2. A role for PS in 
membrane binding of sTF-His and gCΔ457t was implied by an ~ 2.5-
fold increase of the Kd,app values when PS was omitted from the 
Ni-chelating vesicle.
The binding of FVIIa to sTF-His or gCΔ457t in the presence 
of NiPCPS (Figure 5C) or NiPC (Figure 5D) was measured enzy-
matically by limiting the detection of FXa generation to the con-
centration of FVIIa. Whereas both the gCΔ457t/NiPCPS and 
sTF-His/NiPCPS pairs exhibited similar Vmax values (Figure 5C), 
reactions involving sTF-His/NiPC yielded a Vmax value that was 
two-fold greater than those with gCΔ457t/NiPC (Figure 5D), im-
plying an effect of PS on the number of gCΔ457t-FVIIa binding 
sites. NiPCPS-tethered sTF-His had a binding affinity (Table 2) 
consistent with earlier reports addressing FVIIa-binding to mem-
brane-inserted full-length TF (Kd,app ~ 10 ρmol/L). This effect was 
independent of the presence of PS. The Kd,app describing the inter-
action of gCΔ457t with FVIIa was ~20 nmol/L, which was also not 
influenced by the presence of PS.
With both lipid- and FVIIa-binding affinities known, the con-
centration of the lipid/cofactor/enzyme complex can be estimated 
and, consequently, the Michaelis-Menten kinetics were derived 
(Figure 5E). The Km for FX activation by FVIIa in the presence of 
either sTF-His or gCΔ457t was ~0.15 µmol/L (Table 3). The turnover 
number (kcat) for FX conversion was moderately higher in the pres-
ence of sTF-His (3.8 seconds-1) compared with gCΔ457t (2.5 sec-
onds-1). Nonetheless, sTF-His and gCΔ457t had comparable catalytic 
efficiencies (kcat/Km) with a nominal 1.4-fold difference. Therefore, 
a large part of the differential efficacy of sTF-His vs gCΔ457t is at-
tributed to their relative affinity for FVIIa.
4  | DISCUSSION
Here, we demonstrated that the coagulation tenase cofactor func-
tion of HSV1-encoded gC is analogous to that of TF using solu-
bilized recombinant forms, gCΔ457t and sTF-His (respectively), in 
well-defined biochemical studies. Similar to full-length TF and sTF-
His,43,48 gCΔ457t required orientation on a membrane as shown 
by enhanced activity in the presence of vesicles that contained Ni-
chelating lipid to facilitate association of the C-terminal poly-His. 
Direct binding to gCΔ457t of the tenase substrate, FX, was demon-
strated, which confirmed previous studies.37 The protease subunit 
of tenase, FVIIa, was shown for the first time to also associate with 
gCΔ457t, which acted like a receptor for FVIIa. The gCΔ457t-FVIIa 
interaction was enhanced by FX. Thus, gC is a constituent of a ter-
nary protein complex that is localized to a membrane surface by the 
availability of substrate, like the TF-dependent tenase.
In addition to the Ni-chelating lipid that anchors gCΔ457t to the 
membrane, the presence of PS was important for FVIIa-dependent 
FX activation. The FX-mediated high affinity FVIIa assembly into 
the gCΔ457t/NiPCPS tenase required PS, which may in part be ex-
plained by the intrinsic affinity of FX for PS-containing vesicles being 
much greater than FVIIa (Kd ~0.2 and ~15 µmol/L, respectively) 
29,30 
and a consequent pseudo-receptor effect. Thus, the PS contribu-
tion to the overall gCΔ457t/FVIIa/FX tenase complex formation is 
predominantly attributed to FX, presumably via the Gla-domain.49 
In contrast, PS provided minimal contributions to FVIIa binding to 
gCΔ457t indicating that the Gla-domain-dependent association of 
FVIIa with PS is a relatively unimportant variable in cofactor/enzyme 
complex formation. These observations parallel the mechanism of 
sTF-His.43,50 gCΔ457t/FVIIa complex formation was enhanced con-
siderably by FX even in the absence of membrane, demonstrating a 
Gla-independent aspect of viral tenase assembly. Thus, the utility of 
vesicles comprised of Ni-chelating lipid and PS combinations has re-
vealed congruent characteristics for the various protein-membrane 
interactions in gCΔ457t/FVIIa/FX and sTF-His/FVIIa/FX.
The mixture of gCΔ457t and sTF-His with saturating FVIIa, FX 
and NiPCPS resulted in the generation of FXa consistent with the 
sum of the gCΔ457t and sTF-His individually measured. To evaluate 
the tenase function of full-length gC and TF within the full comple-
ment of the intricate environment of the virus envelope surface, our 
unique virus panel of HSV1/TF+/gC+, HSV1/TF+/gC-, and HSV1/TF-/
gC+ were compared. Interestingly, the additive effect with purified 
proteins was not observed on the HSV1 surface, where FXa gener-
ation was enhanced by gC only when TF or purified sTF-His was also 
available. This synergistic effect on gC by TF may imply a direct gC-TF 
interaction. Because four methods (ie, MST, crosslinking, nondena-
turing electrophoresis, and ELISA) failed to detect such an association 
either on the virus or between purified proteins (data not shown), an 
additional host or virus-encoded constituent(s) may be involved in the 
macromolecular FX activating complex on the virus surface.
Because FX enhances the gCΔ457t/FVIIa interaction, it follows 
that the association of FVIIa with gCΔ457t was ~ 10-fold weaker 
when determined by MST in the absence of FX compared with the 
TA B L E  2   Equilibrium binding constants derived from 








sTF-His NiPCPS 33.8 (23.0-44.4) 7.0 × 10−3 
(4.4 × 10−3-
9.6 × 10−3)
sTF-His NiPC 13.4 (5.6-21.2) 8.9 × 10−3 
(2.9 × 10−3-
1.5 × 10-4)
gCΔ457t NiPCPS 48.0 (26.0-70.0) 21.5 (18.3-24.7)
gCΔ457t NiPC 19.1 (7.4-30.7) 18.0 (8.7-27.3)
TA B L E  3   Kinetic effects of gCΔ457t compared to sTF on FX 
activation




sTF-His NiPCPS 0.16 ± 0.02 3.8 ± 0.5 23.6 ± 1.4
gCΔ457t NiPCPS 0.14 ± 0.02 2.5 ± 0.3 16.6 ± 1.0
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kinetically linked FX-activation method. A possible contributor to the 
higher Kd was the effect of amine modification of FVIIa to produce 
FVIIa-R. However, this was unlikely a contributor because FVIIa-R 
retained tenase activity comparable to unlabeled FVIIa where the 
fluorophore stoichiometry per FVIIa was carefully limited to ~ 1:1. 
As an additional precaution during MST equilibrium measurements, 
benzamidine prevented proteolytic activity without altering gCΔ457t 
binding to FVIIa (data not shown). TF-FVIIa binding measurements by 
others have reported a wide range of Kd values, because of variable 
contributions of FX and aPL depending on experimental conditions 
and the limited sensitivity of some approaches that required protein 
concentrations in vast excess over Kd.
48 Surface plasmon resonance 
using relipidated TF yielded a Kd in the ρmol/L range 
48 that was very 
similar to that obtained by enzymatic assays or fluorescence anisot-
ropy.47,51,52 However, the TF/FVIIa/aPL complex did not dissociate to 
completion over the course of the measurement, potentially compro-
mising the accuracy of Kd derivation as recognized by the authors. 
We show a high-affinity recruitment of FVIIa (~30 ρmol/L) into the 
sTF-His/FX complex on a NiPCPS membrane measured consistently 
by either MST or enzymatic assays, supporting the importance of 
membrane orientation- and FX-dependent macromolecular assembly 
and resolving any literature discrepancy.
Our work has revealed a novel interaction between virus-en-
coded gC, and the initiating coagulation protease FVIIa, that requires 
FX and aPL for optimal complex formation. This mechanism parallels 
that of the physiological hemostatic trigger TF and implies molecu-
lar mimicry. The role of gC in enhancing FX activation, even in the 
absence of TF, is a probable contributor to viral infection 30 and to 
hemostatic abnormalities correlating to atherosclerotic and throm-
botic propensity.5-6,15-18,21
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